Pharmacological treatment of attention-deficit/hyperactivity disorder in children with autism spectrum disorder and epilepsy: Current evidence and safety considerations

Attention-deficit/hyperactivity disorder (ADHD) symptoms frequently coexist with autism spectrum disorder (ASD) and epilepsy; however, seizure manifestations, antiseizure medication (ASM) effects, sleep disturbances and sensory or emotional factors can complicate diagnosis and treatment. Current evidence on ADHD pharmacotherapy in children with these overlapping conditions was synthesized in a narrative review of English-language clinical studies, reviews and professional guidance published mainly between 2020 and 2025, together with the 2018 International League Against Epilepsy consensus. Interpretation focused on diagnostic differentiation, seizure-related safety, tolerability and functional outcomes. Evidence specifically involving all three conditions remains limited. Methylphenidate has the strongest published support for core ADHD symptoms in children with epilepsy, particularly when seizures are stable and standard therapeutic doses are used. Atomoxetine is an alternative when stimulant treatment is unsuitable or poorly tolerated; alpha-2 adrenergic agonists may address selected symptoms of hyperactivity, impulsivity, or hyperarousal. Antipsychotics can be used for defined ASD-related behavioral indications but should not be regarded as primary ADHD treatments. A proposed clinical pathway links multisource diagnostic confirmation, seizure and ASM baseline assessment, individualized medication selection, gradual titration, seizure diaries, monitoring of sleep, appetite, growth, vital signs and mood and functional feedback from caregivers and schools. The suggested pathway provides an organizational aid rather than a validated risk prediction instrument. Medication decisions should prioritize demonstrable improvements in participation, learning and safety while maintaining neurological follow-up.